CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

From Pharmafile

January 14, 2026

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech
Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100 million fund designed to invest in pre-clinical and early clinical-stage biotechnology companies.

View original article on pharmafile.com

Most Recent

47+ large US data center projects were delayed, withdrawn, or blocked in 2026; Bernstein says ~35% of the planned US data center pipeline is credible

A vast bet on the future of the technology is running into the unforgiving economics of the physical world

Oct 17, 2026

AI debt worries mount as CoreWeave's bond yield tops 15%, insuring SoftBank debt gets pricier, and some Oracle debt trades near 80 to 90 cents on the dollar

Debt trouble at CoreWeave, Oracle and SoftBank raises questions about whether there are broader problems with the data center build-out.

Oct 17, 2026

Exclusive: ‘I’ve seen this movie before’: A Michigan-raised ex-Tesla exec raises $45 million to break China’s grip on batteries

Steven Prast is old enough to remember when a mobile phone came in a bag. It was too heavy to carry around, so most people mounted it in the car.

Oct 17, 2026

Anthropic is consulting law firms on deal negotiation tactics as it develops AI agents to negotiate on humans' behalf and interact with AI counterparts

Tech companies are being forced to confront the rules of negotiation when machines act on humans' behalf

Oct 17, 2026

Similar Posts

Arkin Capital closes on $100m for Bio Ventures III

With LPs such as Phoenix Insurance, Clal Insurance and Amitim Pension Funds, the fund will invest in 10-12 companies.

Jan 11, 2026

Catalio Capital closes over $400M Fund IV

Catalio Capital Management announced the closing of its more than $400 million Fund IV. The fund will continue the firm’s thesis of backing healthcare and biotechnology companies.

Jul 1, 2025

Arkin raises $100m for early-stage biotech fund

The main investors in Arkin Bio Ventures III together with Arkin Capital are Israeli institutional investors including Phoenix Finance, Clal Insurance, and Amitim pension fund

Jan 12, 2026

Arkin Holdings raises $270 million for new biotech fund

The new fund, which will be named Arkin Bio-Capital, intends to invest in 8-10 companies that are developing innovative medicine and plan on going public in the near future

Aug 31, 2025